NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

Proceeds will go toward commercial expansion of its gene expression-based diagnostic tool called Afirma Thyroid FNA Analysis for thyroid cancer and the development of its product pipeline.

GE Ventures was a new investor in the round. Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, Versant Ventures, and all previous investors participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.